Company News

No7 Launches New Future Renew Damage Reversal with Novel Peptide Technology

Brand conducts 37 studies on more 4,200 people, including two clinical and 23 user trials—the most extensive and diverse testing program in its history.

Author Image

By: Christine Esposito

Editor-in-Chief

Leading mass market skincare brand No7 this week is rolling out Future Renew Damage Reversal, which scientists contend represents one of the biggest developments in the brand’s history. The line centers around a breakthrough super peptide created by No7 and the University of Manchester in the UK. The No7 team conducted blind clinical trials on the novel ingredient that No7 R&D contends “biohacks” the skin’s own natural repair process.  The matrix-derived peptide blend contains two brand-...

Continue reading this story and get 24/7 access to Happi for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Happi Newsletters